fbpx Skip to main content

WEDNESDAY, Dec. 9, 2020 (HealthDay News) — More than half of severely obese patients undergoing Roux-en-Y gastric bypass (RYGB) have diabetes remission, according to a study published online Dec. 3 in the Journal of Clinical Endocrinology & Metabolism.

Jonathan Q. Purnell, M.D., from the Oregon Health & Science University in Portland, and colleagues compared diabetes prevalence and remission rates during seven years of follow-up after RYGB and laparoscopic gastric banding (LAGB) in an observational cohort of 2,256 adults with severe obesity at 10 U.S. hospitals.

The researchers found that diabetes remission occurred in 57 percent (46 percent complete; 11 percent partial) and in 22.5 percent (16.9 percent complete; 5.6 percent partial) after RYGB and LAGB, respectively. Remission was greater in younger participants and those with shorter diabetes duration, higher C-peptide levels, higher homeostatic model assessment (HOMA) percentage B (a measure of ß-cell activity), and lower insulin usage at baseline and with greater postsurgical weight loss following both procedures. Reduced HOMA insulin resistance was associated with a greater likelihood of diabetes remission after LAGB, while after RYGB, increased HOMA percentage B predicted remission. Diabetes remission remained nearly fourfold higher for RYGB versus LAGB after controlling for weight lost.

“Our large study confirms the importance of weight loss on inducing diabetes remission, but also finds gastric bypass has benefits independent of weight,” Purnell said in a statement. “If we can understand what these benefits are, it could lead to new diabetes treatments.”

One author disclosed financial ties to a medical device company; a second author disclosed ties to a pharmaceutical company.

You May Also Like::  CDC: Most Teens Do Not Meet Recommended Fruit, Veggie Intake

Abstract/Full Text (subscription or payment may be required)

“Keeping up with the indications and adverse reactions to immune checkpoint inhibitors can be a full-time job. Cutaneous side effects occur in up to 45% of patients treated with ipilimumab and 34% of patients treated with nivolumab and pembrolizumab.” https://bit.ly/3FGtxtd

.@spfnomt: This month’s #DermWorld article “Estate planning 101” is especially important for young physicians to read. The long, all-consuming years between adolescence and physicianhood can become a blur...https://bit.ly/3FxOtCv

That’s a wrap #AAD2023! 5 days of soaking up knowledge from dermatologists on topics such as hidradenitis, melasma, & dietary triggers of common dermatoses.

I LOVED the #womenshealth focused sessions on vulvar dermatoses and pregnancy medication safety.


New approach uses microbiome to treat skin disease by repairing the injured microbiome that allowed inflammation to flare up in the first place, rather than reducing the inflammation after the fact. https://bit.ly/3Jt6H9v

Load More